A carregar...
Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival
Receptor tyrosine kinase AXL (RTK-AXL) is regarded as a suitable target in glioblastoma (GBM) therapy. Since AXL kinase inhibitors are about to get approval for clinical use, patients with a potential benefit from therapy targeting AXL need to be identified. We therefore assessed the expression patt...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5584143/ https://ncbi.nlm.nih.gov/pubmed/28881571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18468 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|